Allergy & Immunology
Chronic Spontaneous Urticaria
Expert Roundtables Podcast: Optimizing the Diagnosis and Treatment of Chronic Spontaneous Urticaria
Presently, several targeted therapies are available for chronic spontaneous urticaria (CSU) when second-generation nonsedating H1 antihistamines fail, including oral and subcutaneous options. In this CSU podcast, our featured experts explain how, despite these advancements, gaps in CSU care persist, particularly within primary care. This underscores the need for timely referral to an allergist/immunologist or dermatologist to ensure appropriate diagnosis and treatment of the disease.
AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel. Chronic urticaria guidelines: 2026 AAAAI/ACAAI Joint Task Force (JTF) on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Updated June 9, 2026. Accessed September 15, 2026. https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf
Ansotegui IJ, Bousquet J, Canonica GW, et al. Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review. Curr Med Res Opin. 2024;40(8):1297-1309. doi:10.1080/03007995.2024.2378172
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. doi:10.1111/all.15090



